Table 3.
Associations between previously identified AME SNPs and relative concentrations of arsenic species measured in both urine and bloodc
| Regression coefficient, β (P value)a | ||||
|---|---|---|---|---|
| Arsenic speciesb | rs61735836 (21:47572887)MAF(T): 6.5% | rs4919690 (10:104616500)MAF(C): 9.6% | rs11191492 (10:104747534)MAF(G): 16.1% | rs191177668 (10:104635687) MAF(T): 0.7% |
| DMA% | ||||
| Urine | –3.9 (1.2 × 10–4) | –2.6 (1.3 × 10–3) | 2.1 (1.2 × 10–3) | –10.8 (1.3 × 10–4) |
| Blood | –2.7 (5.1 × 10–4) | –2.2 (2.0 × 10–4) | 1.1 (0.03) | –4.4 (0.024) |
| MMA% | ||||
| Urine | 1.0 (0.060) | 1.4 (1.1 × 10–3) | –0.84 (0.01) | 5.3 (2.6 × 10–4) |
| Blood | 2.2 (1.6 × 10–3) | 1.4 (0.01) | –0.90 (0.05) | 2.9 (0.11) |
| iAs% | ||||
| Urine | 2.9 (2.0 × 10–4) | 1.2 (0.05) | –1.3 (0.01) | 5.4 (0.01) |
| Blood | 0.45 (0.36) | 0.84 (0.03) | –0.19 (0.56) | 1.55 (0.21) |
| Total | ||||
| Urinea | –6.1 (0.70) | –13.4 (0.29) | 5.7 (0.59) | –18.3 (0.68) |
| Blood | –0.12 (0.92) | –0.89 (0.39) | –0.78 (0.36) | 1.9 (0.59) |
aTotal urinary arsenic concentration (sum of iAs, MMA, and DMA) is creatinine adjusted.
bEstimates are from mixed-effects models, as arsenic species were measured at week 0 and week 12, and both timepoints were analyzed together in a single model. Sample sizes for week 0: urinary total arsenic (n = 301), urinary arsenic species (n = 290), blood total arsenic and arsenic species (n = 253). Sample sizes for week 12: urinary total arsenic and arsenic species (n = 222), blood total arsenic and arsenic species (n = 190). Total observations: urinary total arsenic (n = 523), urinary arsenic species (n = 444), blood total arsenic and arsenic species (n = 443).
cMultivariate model adjusted for age, sex, and ancillary study.